List of Contributors
Preface
PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT
Chapter 1. Drug Development in Oncology 101 by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhD
Chapter 2. Pharmacogenomics by Molly Graveno, PharmD, BCOP
Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MD
Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MS
PART 2. CLASSICAL CYTOTOXIC AGENTS
Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhD
Chapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MD
Chapter 7. Antifolate Antimetabolites by Justin Lawson, PharmD, BCOP
Chapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhD
PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS
Chapter 9. Drugs Targeting DNA Repair, Cell Cycle and Apoptosis by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD
Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhD
Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhD
PART 4. ORGAN-TARGETED APPROACHES
Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhD
Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MD
Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MD
Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MD
PART 5. IMMUNE-TARGETED STRATEGIES
Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MD
Chapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, Immunoconjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOP
Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors, Vaccines, Bispecifics, and Engineered T Cells by Mark Yarchoan, MD and Elizabeth Jaffee, MD
Index
